readthroughSign in
Nov 18, 2026Clinical readout

Telomir Pharmaceuticals taps Linical as CRO for TNBC trial of Telomir-Zn

The company said it signed agreements with the global CRO to help run its FDA-cleared Phase 1/2 study, with clinical initiation targeted for the first quarter of 2027.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) announced on November 18, 2026 that it has selected Linical, a global contract research organization with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).1

According to the filing, Telomir has put in place a Master Services Agreement and a clinical trial Work Order with Linical, setting up the operating structure needed to move the study toward its planned start, which the company is aiming for in the first quarter of 2027.1 The engagement comes after the FDA's clearance of Telomir's Investigational New Drug application, which the company described as an operational milestone on the path to clinical execution.1

On Linical's background, the release states the CRO has more than two decades of experience in oncology clinical development, including breast cancer and other solid tumors, with roughly half of that oncology work concentrated in early-phase studies.1 Its services are described as covering work across Phase 1 through Phase 4 development, including trial startup, coordination with investigator sites, patient recruitment, monitoring, project management, biometrics, and regulatory support.1

Describing the drug candidate, Telomir said Telomir-Zn is an investigational oral therapy intended to act on epigenetic pathways by adjusting how cells manage metals internally, with the aim of switching back on tumor suppressor genes tied to cancer growth.1 The company added that the approach centers on the role intracellular metals, particularly iron, play in epigenetic regulation, since some cancers including TNBC rely heavily on iron-related pathways for uncontrolled growth; by changing the availability of these metals inside cells, Telomir-Zn is designed to block certain iron-dependent epigenetic enzymes and potentially restore suppressor gene activity.1

The planned study will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of Telomir-Zn given alone to patients with advanced or metastatic TNBC.1 The company said it continues to target the first quarter of 2027 for clinical initiation as it advances trial preparations with Linical.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.